021-51111890
购物车（0）
sales@molnova.cn
Lecanemab
CAS No. 1260393-98-3
Lecanemab ( —— )
产品货号. M36805 CAS No. 1260393-98-3
Lecanemab (BAN-2401) is an IgG1 monoclonal antibody targeting soluble aggregated β-amyloid (Abeta) with activity against oligomers, protofibrils, and insoluble protofibrils, and may be useful in the study of Alzheimer's disease (AD)-induced mild cognitive impairment and mild AD dementia.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥2519 | 有现货 |
|
| 5MG | ￥3900 | 有现货 |
|
| 10MG | ￥5588 | 有现货 |
|
| 25MG | ￥8446 | 有现货 |
|
| 50MG | ￥11652 | 有现货 |
|
| 100MG | ￥15071 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Lecanemab
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Lecanemab (BAN-2401) is an IgG1 monoclonal antibody targeting soluble aggregated β-amyloid (Abeta) with activity against oligomers, protofibrils, and insoluble protofibrils, and may be useful in the study of Alzheimer's disease (AD)-induced mild cognitive impairment and mild AD dementia.
-
产品描述Lecanemab (BAN-2401) is an IgG1 monoclonal antibody targeting soluble aggregated β-amyloid (Abeta) with activity against oligomers, protofibrils, and insoluble protofibrils, and may be useful in the study of Alzheimer's disease (AD)-induced mild cognitive impairment and mild AD dementia.
-
体外实验——
-
体内实验——
-
同义词——
-
通路Membrane Transporter/Ion Channel
-
靶点Beta Amyloid
-
受体Beta Amyloid
-
研究领域——
-
适应症——
化学信息
-
CAS Number1260393-98-3
-
分子量
-
分子式——
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES——
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
产品手册
关联产品
-
Pinostrobin
Pinostobin 是一种有效的类黄酮诱导剂，对 Aα2(25-35) 诱导的 PC12 细胞神经毒性发挥神经保护作用。
-
Trontinemab
Trontinemab 是一种双特异性人源 IgG1-κ 抗体，靶向淀粉样蛋白 β A4 前体蛋白 (APP) 和转铁蛋白受体 p90, CD71 (TFRC)。Trontinemab 可用于阿兹海默症的研究。
-
Lecanemab
Lecanemab (BAN-2401) is an IgG1 monoclonal antibody targeting soluble aggregated β-amyloid (Abeta) with activity against oligomers, protofibrils, and insoluble protofibrils, and may be useful in the study of Alzheimer's disease (AD)-induced mild cognitive impairment and mild AD dementia.
